AstraZeneca Invests $2 Billion in Summit Therapeutics Partnership
Source Summary
AstraZeneca is investing $2 billion in Summit Therapeutics to collaborate on testing Summit's PD-1/VEGF bispecific ivonescimab alongside AstraZeneca's antibody-drug conjugates. The partnership aims to explore combined therapeutic approaches in oncology.
Why it matters
The $2 billion investment signals AstraZeneca's commitment to expanding its oncology pipeline through strategic partnerships and combination therapies.
